Growth Metrics

Conmed (CNMD) Asset Writedowns and Impairment (2021)

Conmed posted quarterly Asset Writedowns and Impairment of $899000.0 for Q3 2021.

Conmed (CNMD) has 1 years of Asset Writedowns and Impairment data on file, last reported at $899000.0 in Q3 2021.

  • For the quarter ending Q3 2021, Asset Writedowns and Impairment changed N/A year-over-year to $899000.0; the trailing twelve-month figure through Dec 2022 stood at $899000.0 (changed N/A YoY), and the FY2025 full-year result was $363000.0, changed N/A from the prior year.
  • Asset Writedowns and Impairment for Q3 2021 stood at $899000.0.
  • Across five years, Asset Writedowns and Impairment topped out at $899000.0 in Q3 2021 and bottomed at $899000.0 in Q3 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Conmed 1.06 Bn 1.02 Bn 183.45 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2021 899,000.00
Sep 30, 2021 899,000.00